

NCCN Ovarian Cancer Guidelines V.2.2011 – Interim Update Teleconference –11/08/10

Guideline Request	Panel Discussion	References	Vote		
			YES	NO	Abstain
<p>Internal request: Review the clinical trial data on bevacizumab in the upfront and maintenance setting.</p> <p>External request: Submission from Genentech.</p>	<p>The panel discussed the recently reported results from two phase III randomized trials. The first trial, GOG-0218, assessed carboplatin/paclitaxel/ bevacizumab ± maintenance bevacizumab compared to carboplatin/paclitaxel alone in the upfront setting. The second trial, ICON7, assessed carboplatin/paclitaxel alone compared to carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in the upfront setting. The NCCN Ovarian Cancer panel agreed that until there are more mature data from these trials, the routine addition of bevacizumab to upfront therapy with carboplatin/paclitaxel and the use of bevacizumab as maintenance therapy are not recommended.</p>	<ol style="list-style-type: none"> Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract LBA1. Available at: http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA1 Perren T, Swart AM, Pfisterer J, et al. ICON7: A Phase III gynaecologic cancer interGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Presented at the 35th European Society for Medical Oncology in Milan, Italy; October 8-12, 2010. ESMO Oral Presentation. 	16	0	1